Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is an innovative biotechnology firm concentrated on oncology. Established in 2015 and headquartered in South San Francisco and La Jolla, California, the company is dedicated to the discovery and development of precision medicine therapies for genetically defined patient groups. Their focus areas include synthetic lethality and immuno-oncology, targeting DNA damage repair mechanisms and the tumor microenvironment, respectively.
IDEAYA's pioneering approach leverages molecular diagnostics to identify and develop targeted therapeutics. The company's leading product candidate, IDE196, is a potent inhibitor of protein kinase C (PKC), aimed at treating cancers with GNAQ or GNA11 mutations. In addition, IDEAYA is advancing several clinical programs, such as the darovasertib program, which is currently in Phase 2 trials for uveal melanoma (UM) and has shown promising results in tumor shrinkage and eye preservation.
In synthetic lethality, IDEAYA's IDE397 targets methionine adenosyltransferase 2 alpha (MAT2A) in solid tumors with MTAP deletion, a condition prevalent in 15% of solid tumors. The IDE397 program includes both monotherapy and combination trials with other investigational drugs.
Financially, IDEAYA is robust with cash reserves exceeding $941.4 million as of Q1 2024, ensuring operational funding through 2028. Key investors include 5AM Ventures, Canaan Partners, and Celgene. The company has formed strategic collaborations with major pharmaceutical players like Pfizer, Amgen, Gilead Sciences, GSK, and Merck to amplify its research and clinical capabilities.
IDEAYA's scientific advisory board is composed of esteemed researchers, including a Nobel laureate and members of the National Academy of Sciences, underscoring the company's commitment to groundbreaking research.
Recent developments are promising: IDEAYA reported favorable Phase 2 trial results for IDE196 in UM, with significant tumor reduction and eye preservation rates. Additionally, a collaboration with Merck for the IDE161 program aims to tackle endometrial cancer using advanced immunotherapy combinations.
For more detailed updates and financial information, visit IDEAYA's Investor Relations page.
IDEAYA Biosciences reported its Q4 and full-year 2024 financial results, highlighting significant progress across its clinical pipeline. The company ended 2024 with approximately $1.1 billion in cash, cash equivalents, and marketable securities, expected to fund operations into at least 2028.
Key developments include over 230 patients enrolled in the registration-enabling trial for darovasertib in metastatic uveal melanoma, with median PFS readout targeted by year-end 2025. The company reported encouraging Phase 1 expansion results for IDE397 in MTAP-deletion cancers and selected clinical expansion doses for DLL3 TOP1i ADC IDE849.
Financial highlights for Q4 2024 include collaboration revenue of $7.0 million, R&D expenses of $140.2 million, and a net loss of $130.3 million. The full-year 2024 net loss was $274.5 million.
IDEAYA Biosciences (IDYA) has expanded its clinical collaboration with Gilead Sciences to evaluate IDE397, a potential first-in-class MAT2A inhibitor, in combination with Gilead's Trodelvy in MTAP-deletion non-small cell lung cancer (NSCLC). The combination targets two distinct mechanisms in MTAP-deletion solid tumors, with MTAP-deletion occurring in approximately 15% of NSCLC cases, representing a significant portion of the estimated 48,000 U.S. cases annually.
The study will expand the ongoing Phase 1 trial, which currently evaluates the combination in MTAP-deletion urothelial cancer. Under the agreement, both companies retain commercial rights to their respective compounds. IDEAYA will sponsor the study while Gilead provides Trodelvy supply. The company expects to provide clinical program updates in 2025.
IDEAYA Biosciences (NASDAQ: IDYA) has appointed Joshua Bleharski, Ph.D. as Chief Financial Officer, expected to transition into the role by early May. Dr. Bleharski joins from J.P. Morgan, where he served as Managing Director and Global Co-Head of Biopharma in the Healthcare Investment Banking group for nearly 17 years.
During his tenure at J.P. Morgan, Dr. Bleharski advised on financing and strategic transactions exceeding $65 billion in value for biotechnology companies. The company currently has 6 potential first-in-class clinical programs and 3 preclinical programs in development across multiple solid tumor indications.
Dr. Bleharski's background includes positions as Senior Staff Scientist at a private biotechnology company and post-doctoral fellowships at LIAI and UCLA School of Medicine. He holds a BS in Biology from Duke University, a Ph.D. in Immunology from UCLA, and an MBA from UC Berkeley's Haas School of Business.
IDEAYA Biosciences (NASDAQ: IDYA) has announced the grant of non-qualified stock options to two newly hired employees. The Compensation Committee approved options to purchase 62,800 shares of common stock on January 30, 2025, under the company's 2023 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $23.88 per share, matching IDEAYA's closing price on The Nasdaq Global Select Market on the grant date. These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in two major investor relations events in February 2025. The company will be featured at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11th at 1:20 PM ET, where President and CEO Yujiro S. Hata will participate in a fireside chat hosted by Matthew Biegler.
Additionally, IDEAYA will join Citi's 2025 Virtual Oncology Leadership Summit on February 19th at 12:00 PM ET, featuring another fireside chat with CEO Hata, hosted by Yigal D. Nochomovitz. Live audio webcasts of these events will be available on the company's investor relations website, with recordings accessible for 30 days after the events.
IDEAYA Biosciences (NASDAQ: IDYA) announced its participation at the 43rd Annual J.P. Morgan Healthcare Conference and provided 2025 corporate guidance. The company reported $1.2 billion in cash as of September 30, 2024, expected to fund operations into at least 2028.
Key program updates include: darovasertib Phase 2/3 trial progression with over 200 patients enrolled; IDE397 Phase 1/2 study developments; IDE849 clinical program updates in SCLC and NETs; and planned expansion of IDE161 in combination with KEYTRUDA®. The company targets three IND filings in 2025, potentially bringing their clinical-stage precision medicine oncology programs to nine.
Notable milestones include median progression-free survival readout for darovasertib by year-end 2025, Phase 3 trial initiation in first half 2025, and multiple clinical program updates across their pipeline throughout the year.
IDEAYA Biosciences (NASDAQ: IDYA) has secured an exclusive global license outside Greater China for SHR-4849, a Phase 1 DLL3-targeting antibody drug conjugate (ADC) from Hengrui Pharma. The drug targets Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs), showing promising early clinical results with a ~73% response rate in SCLC patients at therapeutic doses. The deal includes a $75M upfront payment and potential milestone payments totaling $1.045B, plus royalties.
In the ongoing Phase 1 trial, SHR-4849 demonstrated 8 partial responses among 11 evaluable SCLC subjects, with manageable safety profile primarily showing Grade 1 or 2 adverse events. IDEAYA plans to file a US IND in H1 2025. The agreement maintains IDEAYA's guided cash runway through at least 2028.
IDEAYA Biosciences (NASDAQ: IDYA) has announced that its Compensation Committee granted non-qualified stock options to a newly hired employee on December 26, 2024. The grant includes options to purchase 31,400 shares of common stock at an exercise price of $25.86 per share, matching the closing price on Nasdaq Global Select Market on the grant date.
The options were granted under the company's 2023 Employment Inducement Incentive Award Plan and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years. The options have a 10-year term and are subject to continued employment.
IDEAYA Biosciences announced that the Independent Data Monitoring Committee (IDMC) has recommended a move-forward dose in Part 2a of their potential registration-enabling Phase 2/3 trial for the darovasertib and crizotinib combination in first-line HLA-A2-negative metastatic uveal melanoma (MUM) patients. The trial has enrolled over 185 patients and received FDA Fast Track designation.
The recommendation allows completion of Part 2a and seamless continuation to Part 2b, targeting potential accelerated approval based on median progression free survival. The combination therapy is being evaluated in two clinical trials, including the Phase 2/3 registration-enabling trial and a separate Phase 2 trial. Additionally, darovasertib is being studied as neoadjuvant monotherapy in primary uveal melanoma, with plans to initiate a Phase 3 registration-enabling study in first half of 2025.
IDEAYA Biosciences (NASDAQ: IDYA) has nominated IDE251 as its development candidate, representing a potential first-in-class KAT6/7 dual inhibitor targeting cancer treatments. IDE251 is specifically designed to target breast and non-small cell lung cancer (NSCLC) with 8p11 amplification, which affects approximately 15% of breast cancer patients and 17.5% of squamous NSCLC cases.
The drug has demonstrated strong and lasting anti-tumor activity in preclinical studies, particularly in biomarker-positive breast and lung xenografts models. IDE251 selectively inhibits both KAT6 and KAT7 epigenetic modulators while avoiding other KAT family members. The company is currently conducting IND-enabling studies and plans to submit an Investigational New Drug (IND) application to the FDA in 2025.
FAQ
What is the current stock price of Ideaya Biosciences (IDYA)?
What is the market cap of Ideaya Biosciences (IDYA)?
What is IDEAYA Biosciences, Inc.?
What is the primary focus of IDEAYA's research?
What is IDEAYA's product pipeline?
Who are IDEAYA's key investors?
Where is IDEAYA Biosciences located?
What recent collaborations has IDEAYA announced?
What significant achievements has IDEAYA made recently?
What is IDEAYA's financial outlook?
Who comprises IDEAYA's scientific advisory board?
How can I stay updated on IDEAYA Biosciences?
